Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Verastem, Inc.NASDAQ: VSTM

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 98.29M shares rose 81.4% year over year, behind the +101.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 17.9% from the prior quarter. Over 3 fiscal years it compounded at +62.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +81.4% toward the trailing-twelve-month pace of +101.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.29M+17.9% QoQ
Last fiscal yearDec 2025
69.31M+94.1% YoY
LTMMar 2026
80.25M+101.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+81.4%——
1 year+94.1%——
3-year CAGR+62.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
69.31M USD
Year-over-year change
+94.1%
4-year CAGR
+47.8%

Weighted Avg Shares vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 weighted avg shares of 80.25M shares is the 4th highest of the 11 companies compared; the peer median is 65.89M shares.
  • Its year-over-year change of +101.5% is the highest of 10, against a peer median of +25.4%.
  • Over three fiscal years its annual growth of +62.5% compares with a peer median of +17.0%.
VSTM Competitors Peer median
Weighted Avg Shares for VSTM and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026345.71M +7.2%+16.4%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
VSTMVerastem, Inc.LTM Mar 202680.25M +101.5%+62.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 202627.33M +25.4%+15.0%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding VSTM) 65.89M+25.4%+17.0%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.